Back to Results
Aurix Therapy in Pressure Ulcers
||A Multi-Center, Prospective, Randomized Trial Comparing the Effectiveness of Aurix Therapy to Usual and Customary Care in Stage II-IV Pressure Ulcers
||Geneve Allison, MD
Aurix is a platelet-rich plasma (PRP) gel used in the treatment of non-healing chronic wounds. The aim of this trial is to demonstrate the effectiveness of complete wound healing in a prospective, open-label, randomized trial in which pressure ulcers will be treated using Aurix in approximately 100 sites in the US. A physician can enroll a patient in the study for Aurix treatment provided inclusion/exclusion criteria are met. Patients will receive Aurix + Usual and Customary Care (UCC) or UCC alone twice a week for the first two weeks and, then, once a week thereafter. The primary endpoint of the trial is to determine the time to heal at 12 weeks pressure ulcers treated with Aurix + UCC versus UCC alone.
- Medicare eligible
- Ulcer of pressure/shear etiology (Stage II, III, IV)
- Debrided ulcer size between 3-200 square cm.
- Subject known to be sensitive to Aurix components (CaCl, thrombin, ascorbic acid) and/or materials of bovine origin
- Stage I pressure ulcers
- Ulcers that are unstageable or of deep tissue morphology that have yet to become an open wound
Subjects will be seen in the clinic and treated with Aurix + UCC or UCC alone twice a week for the first two weeks and, then, once a week thereafter for up to 12 weeks. At each treatment visit, the subject will undergo a blood-draw.